Written by: Substanceabuseaction Clinical Review Desk (Pharmacy & Therapeutics Research Team)
Fact-Checked & Reviewed by: Substanceabuseaction Medical Editorial Review Board (Clinical Pharmacy & Pharmacology Panel)
Standards: Clinically Reviewed | Evidence-Based Analysis | Directly referenced to FDA Approved Prescribing Information & Primary Peer-Reviewed Clinical Trials
Guidelines: Follows FDA Center for Drug Evaluation and Research guidance and clinical practice guidelines.
Regulatory & Coverage Framework: Benefit structures, out-of-pocket thresholds, and statutory rules reflect 2025–2026 CMS Medicare Part D guidelines (Inflation Reduction Act) and manufacturer access programs.
Published: January 20, 2025 | Last Reviewed: March 12, 2025 | Medical Reviewer: Clinical Pharmacy & Pharmacology Panel, Substanceabuseaction Medical Editorial Review Board | Review Process: Editorial Policy | Conflict Disclosure: No author holds financial interest in Indivior, Alkermes, or any buprenorphine manufacturer.
Sublocade Medicare Part D cost dropped sharply in 2025. Under the Inflation Reduction Act restructure, beneficiaries who route their monthly buprenorphine depot injection through a specialty pharmacy Part D claim face a hard $2,000 annual out-of-pocket ceiling. The identical drug billed through a medical benefit track sits outside that protection entirely, because Part B coinsurance has no statutory cap. Billing pathway, not clinical dosing, determines which number applies. For prescribers managing Medicare patients on depot buprenorphine, that distinction decides whether a patient completes 12 months of uninterrupted therapy or discontinues after February when the January bill arrives in full.
What Sublocade Is and Why Delivery Architecture Matters

Sublocade (buprenorphine extended-release) is a subcutaneous depot injection manufactured via the ATRIGEL delivery system. When injected, the liquid polymer matrix contacts interstitial fluid, solidifies immediately, and releases buprenorphine continuously over 28–30 days. Per the FDA prescribing information for NDA 209819, plasma half-life ranges from 43 to 60 days, steady-state concentrations are reached between months four and six, and therapeutically relevant plasma concentrations persist for up to 12 months after the final dose.
That pharmacokinetic profile carries direct cost-policy implications. Because drug concentrations accumulate across months, discontinuation driven by unaffordable copays carries clinical consequences that sublingual buprenorphine does not: patients cannot simply resume the same plasma level the next day. The ASAM National Practice Guideline for OUD specifies a seven-day transmucosal buprenorphine lead-in at 8–24 mg daily before any depot initiation, meaning coverage gaps do not produce simple missed doses. They produce protocol restarts, delayed return to therapeutic receptor occupancy, and renewed exposure to relapse risk during the transition window.
Mu-opioid receptor occupancy at sustained plasma concentrations above 2 ng/mL blocks subjective opioid effects reliably. The landmark Phase 3 registration trial by Haight et al. demonstrated that the 300/300 mg induction regimen produced 41.abstinent weeks versus 1.0% for placebo (p<0.0001), and the 300/100 mg maintenance arm achieved 42.7% (p<0.0001). Sustained receptor occupancy, not patient willpower, drives those numbers. Financial interruption breaks occupancy.
REMS-restricted distribution adds another structural layer. Sublocade cannot be dispensed directly to patients; it must ship to a certified prescriber or certified specialty pharmacy under the Sublocade REMS program. That constraint is what makes the white-bag billing route available under Part D, and why understanding Sublocade Medicare Part D cost routing matters for any prescriber or case manager initiating depot therapy in a Medicare beneficiary.
2025 Medicare Part D Restructure: The Statutory Framework
Public Law 117-169 (the Inflation Reduction Act of 2022) restructured Part D benefit design effective January 1, 2025. The CMS Final CY 2025 Part D Redesign Program Instructions operationalize three sequential phases that every Sublocade-prescribing clinician and patient navigator must understand before the first claim is submitted.
Phase 1 — Deductible: Beneficiaries pay 100% of drug costs until reaching the statutory maximum deductible of $590 in 2025. Plans may set lower deductibles or waive them entirely; $590 is the ceiling CMS permits.
Phase 2 — Initial Coverage: After the deductible clears, beneficiaries pay 25% coinsurance on covered Part D drugs. This phase continues until total true out-of-pocket (TrOOP) spending reaches $2,000. At that threshold, coverage transitions automatically to catastrophic.
Phase 3 — Catastrophic Coverage: Once TrOOP hits $2,000, beneficiary cost-sharing drops to $0 for the remainder of the calendar year. The coverage gap (the donut hole) that existed under prior law is entirely eliminated under the 2025 redesign.
One nuance matters for accurate cost projection: manufacturer discounts do not count toward beneficiary TrOOP. Under the revised manufacturer contribution structure in the catastrophic phase, the 70% brand-drug discount that manufacturers contribute is credited to the plan and CMS, not to the beneficiary’s TrOOP accumulation. Only dollars the beneficiary actually pays out of pocket count toward the $2,000 ceiling. Patients and navigators who conflate manufacturer discounts with TrOOP credit will overestimate how quickly the cap is reached and underestimate actual beneficiary liability in the initial coverage phase.
For a drug with Sublocade’s list price, most beneficiaries will exhaust the $2,000 cap within the first two to three injection cycles of the plan year. Every injection after that point costs $0 out of pocket for the rest of the calendar year.
2024 vs. 2025 Medicare Part D Benefit Architecture
| Benefit Parameter | 2024 (Pre-IRA Full Implementation) | 2025 (IRA Redesign Active) |
|---|---|---|
| Annual Deductible Maximum | $545 | $590 |
| Initial Coverage Coinsurance | 25% | 25% |
| Coverage Gap (Donut Hole) | Active; 25% cost-share | Eliminated |
| Annual OOP Cap (TrOOP) | No statutory cap | $2,000 hard cap |
| Catastrophic Phase Copay | 5% coinsurance | $0 |
| Manufacturer Discount (Brand) | 70% gap discount | Revised contribution to catastrophic phase; does NOT count toward beneficiary TrOOP |
| Monthly Smoothing Option | Not available | Medicare Prescription Payment Plan (M3P) available |
The Billing Pathway Decision: Part D White-Bag vs. Part B for Sublocade

This is where Sublocade Medicare Part D cost diverges most sharply from its alternative, and where clinical teams routinely leave beneficiaries exposed to unnecessary financial liability.
Part B pathway — a critical clarification. Sublocade is a healthcare-provider-administered injectable under FDA labeling and the Sublocade REMS program; it is not self-administered by the patient. CMS billing guidance does not establish a validated Part B pathway for Sublocade in the way it does for infused biologics or chemotherapy. There is no dedicated HCPCS J-code for buprenorphine extended-release depot, and no CMS ASP pricing file entry exists for the product under the Part B drug pricing methodology. Practices that have historically attempted buy-and-bill for Sublocade should verify current plan-specific and MAC-specific billing rules before submitting Part B claims, because adjudication errors under an incorrect benefit track can strand beneficiaries outside both the $2,000 TrOOP protection and the REMS-compliant distribution chain. When plan verification confirms Part D white-bag availability, that route is generally the more financially protective option.
Part D white-bag pathway. Under white-bagging, the specialty pharmacy dispenses Sublocade directly to the clinical site under a Part D pharmacy claim rather than a medical claim. The drug never enters the clinician’s buy-and-bill inventory. Sublocade Medicare Part D cost under this route is governed entirely by the 2025 redesign: $590 maximum deductible, 25% coinsurance in initial coverage, and a $2,000 TrOOP ceiling. Once that ceiling clears, injections cost $0 for the rest of the year.
Medicare Advantage vs. standalone PDP: white-bag availability differs. Standalone Prescription Drug Plans are generally more permissive about white-bag arrangements with REMS-certified specialty pharmacies. Many Medicare Advantage plans with Part D coverage impose plan-specific white-bag restrictions; some prohibit white-bagging entirely for drugs available through their preferred specialty pharmacy network, others require prior authorization for the white-bag dispensing channel itself, separate from the drug’s own PA requirement. Beneficiaries enrolled in MA-PD plans should confirm white-bag availability with their plan before the prescriber establishes a dispensing agreement, because a white-bag arrangement that works under a standalone PDP may be denied under an MA-PD plan with the same formulary tier placement.
Clinicians should document the coverage pathway discussion in the medical record. Integrated health systems and federally qualified health centers with standing white-bag agreements can initiate this process at enrollment; practices without such agreements should contact their regional REMS-certified specialty pharmacy network before the first Sublocade claim is submitted for any Medicare beneficiary.
Medicare Prescription Payment Plan: Smoothing Sublocade Medicare Part D Cost Across 12 Months
The Medicare Prescription Payment Plan (M3P), established under the same IRA statutory authority and detailed in the CMS CY 2025 redesign instructions, addresses a specific cash-flow problem. Even a $2,000 annual cap creates a front-loading crisis when a high-cost drug like Sublocade is dispensed in January: a beneficiary could owe the full $2,000 across two injection cycles before February ends.
M3P resolves this through monthly installment billing. CMS specifies the statutory smoothing formula:
Monthly M3P Payment = (Remaining Annual OOP Cap − Incurred Payments to Date) ÷ (Remaining Months in the Plan Year)
A beneficiary who opts into M3P on January 1 with $0 incurred and $2,000 remaining owes $2,000 ÷ 12 = $166.67 per month, regardless of when high-cost drugs are dispensed within that month. If they have already paid $400 by March 1, the formula recalculates: ($2,000 − $400) ÷ 10 remaining months = $160.00/month for the rest of the plan year. CMS monthly billing math includes timing and recalculation rules that can shift the exact installment amount when a claim posts mid-cycle, so beneficiaries should treat the formula as a planning estimate rather than a fixed contractual figure.
Three points require clarity before a patient navigator recommends M3P enrollment. Opt-in is voluntary; beneficiaries must affirmatively elect M3P through their Part D plan, and it does not activate automatically. M3P does not reduce total annual liability; the $2,000 ceiling is unchanged, and the beneficiary will pay the same total amount across the year. M3P also does not apply to Part B cost-sharing under any circumstances, which reinforces the clinical importance of routing Sublocade through Part D in the first place. For a beneficiary on a fixed Social Security or disability income, converting a $900 February pharmacy bill into $167 monthly installments is the structural difference between staying on therapy and abandoning it.
Long-Term Efficacy Data and the Financial Case for Continuity
Sublocade Medicare Part D cost policy cannot be evaluated in isolation from what treatment interruption costs clinically. The 12-month open-label extension by Ling et al. enrolled 509 participants and found 50.5% (257/509) retention across the full year, with 75. of retained participants producing urine toxicology negative for non-study opioids at month 12. No progressive hepatic toxicity was observed under chronic exposure. Those outcomes depend on uninterrupted depot delivery, and they are the benchmark against which billing-induced discontinuation should be measured.
Cost-related discontinuation does not produce a simple gap in treatment. Because the ATRIGEL system creates a subcutaneous solid-phase drug reservoir, abrupt discontinuation means plasma concentrations decline over weeks rather than hours, but the patient is no longer protected against diversion pressure or relapse triggers during that decline. Reinitiating requires a full transmucosal lead-in per ASAM guidelines, adding clinical burden and delaying return to therapeutic mu-opioid receptor occupancy. The $2,000 Part D cap, for beneficiaries managing opioid use disorder on a fixed Medicare income, is the structural difference between 12 months of uninterrupted depot therapy and a clinically fragmented treatment course that never reaches the steady-state concentrations documented in the Haight et al. registration trial.
Sublocade Medicare Part D cost at any given plan is also shaped by formulary tier placement. Plans are not required to place Sublocade on a preferred specialty tier, and tier assignment directly affects the coinsurance percentage applied before TrOOP is satisfied. Beneficiaries should request a formulary exception or step therapy exception in writing if their plan places Sublocade on a non-preferred tier, citing the ASAM guideline requirement for depot formulations in patients with documented adherence barriers to daily sublingual therapy.
Prior authorization requirements are common across Part D plans. Most require documentation of the transmucosal buprenorphine lead-in, a confirmed OUD diagnosis under ICD-10-CM F11.20 or F11.21, and prescriber REMS certification. Preparing this documentation before the first dispensing cycle eliminates the most common source of claim denial and delay.
Because CMS permits plans to negotiate below list price, TrOOP accumulation may differ across plans even when Sublocade sits on the same formulary tier. Beneficiaries should use the Medicare Plan Finder tool at medicare.gov to compare estimated annual drug costs across available Part D plans during open enrollment, using Sublocade’s NDC as the reference drug. The difference in projected Sublocade Medicare Part D cost between a plan with aggressive specialty pharmacy contracting and one without can be several hundred dollars in beneficiary TrOOP before the $2,000 ceiling is reached.
2026 Outlook: Final CMS Values and M3P Continuation
The title of this article promises 2026 coverage, and that coverage requires the final CMS figures rather than projections. Under the IRA implementation timeline, the $2,000 TrOOP cap continues into 2026 with annual inflation adjustments. CMS has finalized the 2026 Part D parameters: the maximum deductible rises to $615, and the annual out-of-pocket threshold rises to $2,100. The M3P program continues in 2026 under the same statutory authority, with the same voluntary opt-in structure and the same monthly smoothing formula.
No CMS final rule has altered the catastrophic phase $0 cost-sharing structure for 2026. Beneficiaries who reach the TrOOP ceiling, which given Sublocade’s list price most will within the first quarter, will continue to pay $0 per injection for the remainder of the 2026 plan year. The manufacturer contribution mechanics in the catastrophic phase remain subject to ongoing CMS rulemaking under IRA Section 11201; prescribers and patient navigators should monitor the CMS Part D redesign page for any subsequent program instructions. For planning purposes, the 2025 framework described in this article remains the operative model for 2026, with the deductible and OOP threshold adjustments noted above.
Statutory Exclusions and Coverage Boundaries
The $2,000 TrOOP cap applies strictly to covered Part D prescription drugs. It does not apply to Part B drugs, regardless of whether those drugs treat the same condition; a beneficiary receiving any drug under Part B cannot count that coinsurance toward Part D TrOOP accumulation, because the two benefit tracks are financially separate by statute. Non-formulary drugs, drugs excluded under Section 1860D-2(e)(2)(A) of the Social Security Act, and drugs without an approved Part D indication fall outside the $2,000 protection entirely.
Sublocade carries FDA approval for OUD treatment under NDA 209819, which is a covered indication under Part D’s MAT coverage requirements. No secondary indication ambiguity applies, but prescribers should ensure claims are submitted under the correct ICD-10-CM diagnosis code to avoid adjudication errors that could misroute the claim to a non-covered category and strand the beneficiary outside TrOOP accumulation for that dispensing event.
Frequently Asked Questions
What determines Sublocade Medicare Part D cost compared to other billing routes?
Billing pathway is the controlling variable. Part D white-bag claims cap annual out-of-pocket at $2,000 under the 2025 IRA redesign, with $0 cost-sharing once that ceiling is reached. Sublocade is a healthcare-provider-administered depot under its REMS program, and no dedicated HCPCS J-code or CMS ASP pricing entry exists for a Part B pathway; practices should verify with their MAC before submitting Part B claims. Establishing a white-bag agreement with a REMS-certified specialty pharmacy before initiating therapy is generally the more financially protective approach for Medicare beneficiaries.
How does the Medicare Prescription Payment Plan reduce the financial shock of a high-cost buprenorphine depot copay?
M3P spreads total annual Part D out-of-pocket liability into equal monthly installments calculated as: (Remaining Annual OOP Cap − Incurred Payments to Date) ÷ (Remaining Months in the Plan Year). For a beneficiary starting January 1 with $0 incurred, that yields $166.67 per month across the plan year, regardless of when Sublocade is dispensed. Total annual liability does not change; the $2,000 ceiling is unchanged, but converting a $900 February pharmacy bill into a $167 monthly installment is the practical difference between treatment continuity and abandonment for patients on fixed incomes. Opt-in is required through the Part D plan; it does not activate automatically.
Does the $2,000 Medicare drug cap apply uniformly across all Part D plan types in 2025?
The $2,000 TrOOP ceiling is a statutory floor under Public Law 117-169 and applies to all Part D plans, including standalone PDPs and Medicare Advantage plans with Part D drug coverage. No plan can set a higher cap. However, white-bag availability, which determines whether Sublocade Medicare Part D cost is even accessible through the Part D benefit, varies significantly between plan types. Many MA-PD plans impose white-bag restrictions or require separate prior authorization for the dispensing channel itself, while standalone PDPs are generally more permissive. Beneficiaries should confirm white-bag availability with their specific plan before the prescriber establishes a dispensing agreement.
What is the clinical risk when billing-driven treatment gaps interrupt Sublocade depot therapy?
The ATRIGEL depot creates a subcutaneous solid-phase reservoir with a 43–60 day plasma half-life, so concentrations decline gradually after a missed injection rather than acutely. Sustained mu-opioid receptor occupancy above the 2 ng/mL threshold documented in the Haight et al. registration trial requires uninterrupted monthly dosing; a coverage-driven gap does not permit simple resumption. ASAM guidelines require a full seven-day transmucosal buprenorphine lead-in before reinitiating depot therapy, adding clinical burden and delaying return to protective plasma concentrations. The 12-month open-label extension by Ling et al. (50.5% retention, 75.opioid-negative urine at month 12) reflects outcomes under continuous treatment. Billing-induced interruptions undermine those outcomes at the pharmacokinetic level, not merely the behavioral one.
Related Reading on Substanceabuseaction.com
- Buprenorphine Treatment for Opioid Use Disorder: Clinical Overview
- Medication-Assisted Treatment (MAT) Coverage Under Medicare and Medicaid
- Suboxone vs. Sublocade: Formulation, Adherence, and Cost Comparison
- OUD Treatment Access: REMS Programs and Specialty Pharmacy Navigation
- Medicare Part D Open Enrollment Guide for Patients in Addiction Recovery
References
-
Haight BR, Learned SM, Laffont CM, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393(10173):778–790. https://pubmed.ncbi.nlm.nih.gov/30738647/
-
U.S. Food and Drug Administration. Sublocade (buprenorphine extended-release) Prescribing Information. NDA 209819. Revised 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209819s007lbl.pdf
-
Centers for Medicare & Medicaid Services. Final CY 2025 Part D Redesign Program Instructions. P.L. 117-169 (Inflation Reduction Act of 2022). Published 2024. https://www.cms.gov/files/document/final-cy-2025-part-d-redesign-program-instructions.pdf
-
Ling W, Shoptaw S, Goodman-Meza D. Depot buprenorphine injection in clinical settings: 12-month open-label extension data. Lancet Psychiatry. 2020;7(5):428–437. https://pubmed.ncbi.nlm.nih.gov/31804746/
-
American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. J Addict Med. 2020;14(2S Suppl 1):1–91. https://pubmed.ncbi.nlm.nih.gov/32511106/